Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Fits Minervini’s Trend Template with Strong Growth Momentum

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) has become a possible choice for investors using Mark Minervini’s trend-following approach along with high-growth momentum screening. The Minervini Trend Template spots stocks with strong technical traits, uptrends confirmed by moving averages, relative strength, and closeness to 52-week highs, while the High Growth Momentum (HGM) rating checks if the company shows improving fundamentals. This mix aims to find stocks with both price momentum and business growth, a key part of Minervini’s method to spot market leaders before big moves.

Why MIRM Matches the Minervini Trend Template

The Minervini Trend Template needs stocks to meet several technical conditions to confirm a strong uptrend. MIRM meets these:

• Price Above Key Moving Averages: The stock is above its 50-day ($49.79), 150-day ($46.70), and 200-day ($45.57) moving averages, showing continued upward movement.
• Moving Averages Rising: The 50-day, 150-day, and 200-day moving averages are all moving up, supporting the bullish trend.
• Price Strength: MIRM is now within 5.4% of its 52-week high ($54.78) and 40.6% above its 52-week low ($36.86), fitting Minervini’s rule for stocks to be near highs while keeping upside potential.
• Relative Strength: With a ChartMill Relative Strength (CRS) score of 82.74, MIRM beats 82% of all stocks, a sign of leadership in its sector.

These technical points match Minervini’s idea that top-performing stocks often show steady strength across multiple timeframes before big moves.

High Growth Momentum Fundamentals

Beyond technicals, MIRM shows strong growth numbers that attract momentum investors:

• Revenue Growth: The company reported 69.3% year-over-year revenue growth (TTM), with recent quarterly sales rising by 61.2%. This speed-up points to higher demand for its rare disease treatments.
• Earnings Momentum: While still losing money (EPS TTM: -$1.61), MIRM has improved, with EPS growth of 56.6% over the past year. Recent quarters have seen steady gains (44.4% Q2Q growth in the latest quarter).
• Analyst Revisions: Revenue estimates for the next year have gone up by 5.6% over the past three months, showing optimism about future results.

High-growth investors usually look for companies with faster top-line growth and better earnings paths, both of which MIRM displays.

Technical Breakout Potential

ChartMill’s technical analysis report gives MIRM a perfect technical rating of 10/10 and a solid setup rating of 8/10. Key points from the report include:

• Strong Trend: Both short-term and long-term trends are positive, with the stock holding in a tight range ($50.69–$54.78) before a possible breakout.
• Support Levels: Multiple support zones sit below the current price, including at $51.11 (horizontal line) and $49.74–$50.29 (moving averages and trendlines), offering clear stop-loss points.
• Resistance Zone: A move above $53.48 could signal more upside, with lower volatility hinting at buildup before a possible rise.

View the full technical analysis report here.

Conclusion

Mirum Pharmaceuticals makes a strong case for investors following Minervini’s trend-following approach combined with high-growth momentum screening. Its solid technical position, relative strength, and faster revenue growth make it worth further study.

For more stocks that fit this high-growth momentum and trend template strategy, check the High Growth Momentum + Trend Template screen.

Disclaimer: This article is not investment advice. Do your own research before making any investment decisions. Read our full disclaimer here.